Integrated BioPharma Reports Decline in Net Sales and Income for Quarter Ending September 30, 2025

Integrated BioPharma, Inc. reported a decline in financial performance for the three months ending September 30, 2025, with net sales decreasing to approximately $12.7 million, down 6.8% from $13.6 million in the same period last year. The decrease was primarily attributed to reduced sales volumes from key customers, particularly Herbalife and Life Extension, which together accounted for approximately 87% of total net sales. The company's gross profit also fell to $1.0 million, resulting in a gross margin of 8.0%, down from 10.1% in the prior year, as cost of sales decreased at a slower rate than revenue.

The company's net income for the quarter was approximately $123,000, a significant drop from $259,000 reported in the same quarter of 2024. This decline was largely due to a decrease in operating income, which fell by $327,000, despite a reduction in income tax expenses. Selling and administrative expenses remained relatively stable, totaling approximately $857,000 compared to $881,000 in the previous year. The company noted that inflation and tightened labor markets have negatively impacted profit margins, as it struggles to pass increased costs onto customers.

Operationally, Integrated BioPharma's total assets increased to $25.5 million as of September 30, 2025, up from $24.9 million at the end of the previous fiscal year. The company reported a working capital of approximately $14.9 million, reflecting an increase from $14.5 million. Cash reserves also improved, rising to $4.7 million from $3.6 million, supported by net cash provided by operating activities of $1.3 million during the quarter. However, accounts receivable decreased by $1.4 million, indicating a potential slowdown in sales collection.

The company continues to focus on its core business segments, which include Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment generated approximately $12.2 million in sales, while Other Business Lines contributed $522,000. The company is also exploring opportunities for geographic expansion and product adoption, particularly in the nutraceutical market, which remains competitive.

Looking ahead, Integrated BioPharma's management expressed cautious optimism, emphasizing the need to improve operational efficiency and manage costs effectively. The company is aware of the risks posed by economic conditions, including inflation and competition, which could impact future performance. Management believes that current operations, along with available credit facilities, will support working capital requirements through at least November 2026.